Cite
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018)
MLA
Cecilia G Carvalhaes, et al. “Susceptibility Trends of Ceftolozane/Tazobactam and Comparators When Tested against U.S. Gram-Negative Bacterial Surveillance Isolates (2012-2018).” Diagnostic Microbiology and Infectious Disease, vol. 100, no. 1, Mar. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6d042a6185ac16132240694a5f71ef39&authtype=sso&custid=ns315887.
APA
Cecilia G Carvalhaes, Jennifer M. Streit, Dee Shortridge, & Robert K. Flamm. (2020). Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018). Diagnostic Microbiology and Infectious Disease, 100(1).
Chicago
Cecilia G Carvalhaes, Jennifer M. Streit, Dee Shortridge, and Robert K. Flamm. 2020. “Susceptibility Trends of Ceftolozane/Tazobactam and Comparators When Tested against U.S. Gram-Negative Bacterial Surveillance Isolates (2012-2018).” Diagnostic Microbiology and Infectious Disease 100 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6d042a6185ac16132240694a5f71ef39&authtype=sso&custid=ns315887.